



Xelpros™ (latanoprost ophthalmic emulsion) – New formulation approval

- On September 14, 2018, [Sun Pharma](#) announced the [FDA approval](#) of [Xelpros \(latanoprost ophthalmic emulsion\)](#), for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.
- Xelpros is the first benzalkonium chloride (BAK)-free formulation of latanoprost. BAK is a preservative commonly used in topical ocular preparations.
 - Xelpros was developed using proprietary Swollen Micelle Microemulsion (SMM) technology.
 - A BAK-containing ophthalmic solution formulation of [latanoprost](#) is available generically.
- Latanoprost is a prostaglandin analogue that is used as first-line treatment for OAG or ocular hypertension. Latanoprost is believed to reduce IOP by increasing the outflow of aqueous humor.
- In randomized, controlled clinical trials of patients with OAG or ocular hypertension with mean baseline IOP of 23 to 26 mmHg, the mean IOP-lowering effect of Xelpros administered once daily in the evening was up to 6 to 8 mmHg.
- Xelpros is contraindicated in patients with known hypersensitivity to latanoprost, or any other ingredients in the product.
- Warnings and precautions of Xelpros include pigmentation; eyelash changes; intraocular inflammation; macular edema; herpetic keratitis; bacterial keratitis; and use with contact lenses.
- The most common ocular adverse reactions ($\geq 5\%$) with Xelpros use were eye pain/stinging, ocular hyperemia, conjunctival hyperemia, eye discharge, growth of eyelashes, and eyelash thickening.
- The recommended dose of Xelpros is one drop in the affected eye(s) once daily in the evening.
- Sun Pharma's launch plans for Xelpros are pending. Xelpros will be available as an ophthalmic emulsion containing latanoprost 50 mcg/mL (0.005%).



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.